| Title |
Treatment of Crohn’s Disease with Leflunomide as Second-Line Immunosuppression
|
|---|---|
| Published in |
Digestive Diseases and Sciences, October 2007
|
| DOI | 10.1007/s10620-007-9953-7 |
| Pubmed ID | |
| Authors |
Martin H. Holtmann, Anna-Lena Gerts, Arndt Weinman, Peter R. Galle, Markus F. Neurath |
| Abstract |
The aim of this study was to assess the potential of leflunomide, an immunosuppressant in rheumatoid arthritis, as a second-line immunosuppression treatment of patients with Crohn's disease refractory or intolerant to azathioprine. The study cohort consisted of 24 patients. The primary end point was steroid-free remission, and secondary end points were changes in the Crohn's disease activity index (CDAI) and steroid intake, responsiveness of arthralgias and adverse events. Results were expressed in medians (quartiles). The remission rate increased from 21 to 42% by week 16 (P < 0.05). In the intention-to-treat analysis, the CDAI decreased from 219 to 87 (P = 0.018) and the steroid intake from 25 to 3 mg/day (P = 0.033). In the per-protocol analysis, the CDAI decreased from 182 to 87 (P = 0.0183) and the steroid intake from 45 to 4 mg/day (P = 0.0778). Patients with arthralgias improved significantly. However, adverse side effects were frequent. Leflunomide may improve disease activity, especially in terms of arthralgias, and reduce steroid intake. Adverse events were more frequent in our patients than has been reported in controlled studies for rheumatoid arthritis but corresponded to those found in post-marketing studies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 39 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 20% |
| Other | 4 | 10% |
| Researcher | 4 | 10% |
| Student > Bachelor | 3 | 7% |
| Professor | 3 | 7% |
| Other | 8 | 20% |
| Unknown | 11 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 51% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Nursing and Health Professions | 2 | 5% |
| Computer Science | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2021.
All research outputs
#6,815,932
of 23,854,458 outputs
Outputs from Digestive Diseases and Sciences
#1,141
of 4,304 outputs
Outputs of similar age
#23,260
of 73,748 outputs
Outputs of similar age from Digestive Diseases and Sciences
#8
of 34 outputs
Altmetric has tracked 23,854,458 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 4,304 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 73,748 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.